Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 15/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824475 | 0.94 | MAPK11 (0.51) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL6004539 | 0.88 | MAPK11 (0.51) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL4761930 | 0.88 | MAPK11 (0.51) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL4761929 | 0.87 | MAPK11 (0.50) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL6002821 | 0.86 | MAPK11 (0.49) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL4761505 | 0.85 | MAPK11 (0.52) | MAPK11MAPK14KCNH2 | |
| SCHEMBL4824481 | 0.84 | MAPK11 (0.47) | MAPK11MAPK14KCNH2MAP4K4EGFR | |
| SCHEMBL3373577 | 0.84 | MAPK11 (0.59) | MAPK11MAPK14KCNH2MAPK9LMNA | |
| SCHEMBL6004578 | 0.82 | MAPK11 (0.54) | MAPK11MAPK14KCNH2CSNK1DPIN1 | |
| SCHEMBL6004581 | 0.81 | MAPK11 (0.53) | MAPK11MAPK14KCNH2CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | MAPK11 45/4885MAPK14 26/4885KCNH2 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.